Stratec (ETR:SBS) PT Set at €97.00 by Hauck Aufhäuser Investment Banking

Stratec (ETR:SBSGet Rating) received a €97.00 ($103.19) price target from analysts at Hauck Aufhäuser Investment Banking in a report issued on Wednesday, Borsen Zeitung reports. Hauck Aufhäuser Investment Banking’s target price points to a potential upside of 29.16% from the company’s previous close.

Other analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft set a €119.00 ($126.60) target price on shares of Stratec in a report on Wednesday, February 15th. Warburg Research set a €99.00 ($105.32) target price on shares of Stratec in a report on Friday, November 4th.

Stratec Stock Down 1.8 %

Shares of SBS stock opened at €75.10 ($79.89) on Wednesday. The company’s fifty day simple moving average is €83.19 and its two-hundred day simple moving average is €83.49. Stratec has a 52 week low of €72.70 ($77.34) and a 52 week high of €130.60 ($138.94). The company has a quick ratio of 1.65, a current ratio of 3.48 and a debt-to-equity ratio of 38.79. The stock has a market cap of $910.96 million, a P/E ratio of 32.83, a PEG ratio of 10.43 and a beta of 0.30.

About Stratec

(Get Rating)

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers.

See Also

Receive News & Ratings for Stratec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec and related companies with's FREE daily email newsletter.